hlx71
Recombinant proteinexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 30, 2020 (NCT04583228)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Angiotensin-converting enzyme 2INHIBITOR
ACE2 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04583228 | Phase 1 | Nov 30, 2020 | Hengenix Biotech Inc, Parexel |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Hengenix Biotech Inc | For profit | 1 | 1 | 1 | 2020 |
| Parexel | For profit | 1 | 0 | 1 | 2020 |
2 organizations
Page 1 / 1